The continuing bad press about Judah Folkman's work on the Endostatin anti-angiogenesis protein has taken a new turn, with a story in The Wall Street Journal suggesting that the National Cancer Institute and EntreMed Inc. are casting aside scientific discipline in order to pursue human trials of the protein.

Last week's Journal story termed the decision "startling". However, as is often the case with these kinds of shocking revelations, BioCentury was not startled to find out after a few follow up calls that a few pertinent points were missing from the story.